Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.
She has an MA in business and economic reporting from New York University. You can connect with Laura on LinkedIn or Twitter.
Comparing Disease Impact and Activity in Psoriatic Arthritis by Ethnic Background
Patients of South Asian origins who have psoriatic arthritis have a worse clinical phenotype and worse disease impact than patients of North European origins, according to research published in Rheumatology.
Real-World Study: Dupilumab for Atopic Dermatitis More Effective Than Clinical Trial Results
The broadest real-life study of dupilumab in atopic dermatitis (AD) found significant improvements in adults with moderate to severe AD that were even greater than the results reported in clinical trials.
Precision Medicine Could Yield Significant Cost Savings in RA Treatment
A decision-analytic model could save more than $7 million in overall ineffective health care costs per 1000 patients by predicting which patients with rheumatoid arthritis (RA) will have an inadequate response to anti–tumor necrosis factor therapies.
Improved Treatment Options for SMA Present New Opportunities, Challenges
There are now multiple therapeutic options available for spinal muscular atrophy (SMA), a disease once considered incurable; however, there remains a need for additional treatments and better ways to predict treatment response.
SMA Impacts Health-Related Quality of Life for Both Patients and Caregivers
In addition to high health care and societal costs, spinal muscular atrophy (SMA) is associated with a deterioration in the health-related quality of life of both patients and their caregivers in 3 European countries.
More CV Risk Factors Associated With Greater Disease Burden in Psoriatic Arthritis
Cardiometabolic comorbidities are a considerable burden in patients with psoriatic arthritis, and patients who had a higher number of cardiovascular (CV) risk factors had greater disease activity, according to a study in Medicina.
After FDA Approval, EMA Accepts Marketing Authorization Application for First Oral SMA Therapy
The FDA approved the drug on August 7, and on August 17, the European Medicines Agency (EMA) accepted the marketing authorization application for the spinal muscular atrophy (SMA) treatment.